Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n ¼ 15) or with vitamin C (VC)-(n ¼ 15), vitamin E (VE)-coated dialyzer (n ¼ 15), or ERW treatment (n ¼ 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H 2 O 2 , after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC4ERW4VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients.
Chronic hemodialysis (HD) patients increase erythrocyte susceptibility to hemolysis and impair cell survival. We explored whether electrolyte-reduced water (ERW) could palliate HD-evoked erythrocyte impairment and anemia. Forty-three patients undergoing chronic HD were enrolled and received ERW administration for 6 month. We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin (metHb)/ferricyanide reductase activity, plasma metHb, and proinflammatory cytokines in the chronic HD patients without treatment (n ¼ 15) or with vitamin C (VC)-(n ¼ 15), vitamin E (VE)-coated dialyzer (n ¼ 15), or ERW treatment (n ¼ 15) during an HD course. The patients showed marked increases (15-fold) in blood reactive oxygen species, mostly H 2 O 2 , after HD without any treatment. HD resulted in decreased plasma VC, total antioxidant status, and erythrocyte metHb/ferricyanide reductase activity and increased erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and plasma metHb. Antioxidants treatment significantly palliated single HD course-induced oxidative stress, plasma and RBC PCOOH, and plasma metHb levels, and preserved erythrocyte metHb /ferricyanide reductase activity in an order VC4ERW4VE-coated dialyzer. However, ERW had no side effects of oxalate accumulation easily induced by VC. Six-month ERW treatment increased hematocrit and attenuated proinflammatory cytokines profile in the HD patients. In conclusion, ERW treatment administration is effective in palliating HD-evoked oxidative stress, as indicated by lipid peroxidation, hemolysis, and overexpression of proinflammatory cytokines in HD patients. In patients undergoing hemodialysis (HD), the interaction of blood with non-biological materials of the extracorporeal circuit can activate polymorphonuclear leukocytes to produce quantities of reactive oxygen species (ROS), which impair neighboring tissues/cells (including RBCs) and evoke an inflammatory response. [1] [2] [3] [4] The plasma levels of proinflammatory cytokines (e.g., interleukin (IL)-1, IL-6, tumor necrosis factor-a, and C-reactive protein) are significantly elevated in uremic patients on dialysis, 3, 5 and the expression can be augmented further even after a single HD session. 3, 6 Increased oxidative stress and proinflammatory cytokines in HD patients are related to malnutrition, 7 resistance to erythropoietin therapy, 8 cardiovascular events, 9,10 and high mortality. 11 There is increasing evidence that oxidative stress plays a key role in the genesis and severity of dialysis anemia. [12] [13] [14] It reduces RBC survival, 15 impairs the effect of erythropoietin, 16, 17 and increases the susceptibility to hemolysis owing to inflammatory, infectious, and mechanical stimuli. 13, 18 During the process of oxidative stress, RBCs are subject to membrane lipid peroxidation and susceptible to destruction. [19] [20] [21] Increased ROS can oxidize oxyhemoglobin to yield H 2 O 2 and methemoglobin (metHb) 22, 23 that, in turn, leads to tissue hypoxia, 24 endothelial cell G 2 /M arrest, and apoptosis. 25 Increased H 2 O 2 repressed metHb reductase expression in HeLa cells; 26 deficiency of the enzyme, an autosomal recessive trait, results in hereditary methemoglobinemia (hemolysis). 27 A trans-plasma membrane electron transport system (e.g., nicotinamide adenine dinucleotide (reduced form)-ferricyanide reductase and NADH-metHb reductase) is present on RBC membranes and plays a role to reduce cytotoxic ferricyanide/metHb to functional ferrocyanide/ oxyhemoglobin. 28, 29 Intravenous vitamin C (VC)-or vitamin E (VE)-coated dialyzer can improve HD-enhanced erythro-cyte lipid peroxidation and hemolysis via the preservation of NADH-ferricyanide reductase and NADH-metHb reductase. 4 Electrolyte-reduced water (ERW) obtained by electrolysis scavenges O 2 ÀK , H 2 O 2 , and HOCl, 3, 30 and protects DNA from oxidative damage. 30 The protective mechanism of ERW results from active atomic hydrogen with high reducing ability, which can contribute to ROS-scavenging activity, and may participate in the redox regulation of cellular function. 30 Active hydrogen in ERW may be an ideal scavenger against ROS because it does not produce oxidized molecules after reduction like other organic antioxidants (VC, VE, and polyphenols). 31 Our previous data reported that ERW administration diminished HD-enhanced H 2 O 2 and HOCl activity, minimized atherosclerotic, oxidized and inflammatory markers, and partly restored total antioxidant status (TAS) during 1-month treatment. 3 In this study, 6 monthd of HD session was used in this study as in vivo system to evaluate the effects of ERW on dialysis-induced oxidative stress as indicated by erythrocyte lipid peroxidation, erythrocyte reductase activity, and metHb (hemolysis) levels. We also examined the long-term outcome of ERW on hematocrit, erythropoietin dose, and proinflammatory cytokine profiles in patients with end-stage renal disease (ESRD).
RESULTS

ERW-reduced HD-enhanced ROS formation in the blood
An average 15-fold increase in blood ROS activity was noted in patients who underwent HD without ERW treatment. Replacement of ERW could effectively suppress the ROS formation by 75714% in HD patients (Figure 1a) . VC-or VE-coated dialyzer inhibited HD-enhanced ROS by 83711 or 4979%.
Post-HD blood samples obtained from the group were used for examining the effects of several antioxidants. The augmented blood ROS counts were greatly inhibited by an H 2 O 2 scavenger, catalase (by 6878%), and partially depressed by superoxide dismutase (1475%) and epigallocatechin-3-gallate (1675%) (Figure 1b) , indicating that the majority of the blood ROS activity was derived from H 2 O 2 . ERW depressed ROS activity by 6078%.
ERW preserved HD-reduced plasma TAS
In the XERW group, the post-HD plasma VC and TAS levels were significantly decreased ( Figure 2 ). This indicates that HD can cause acute oxidative stress and acute loss of plasma VC. In the VC group, intravenous VC significantly (Po0.05) increased the plasma VC and TAS levels in ESRD patients receiving HD. Patients for whom the VE-coated dialyzer was used did not seem to have restored plasma VC and TAS levels. ERW treatment could restore plasma VC and TAS levels. In all four groups, there was no significant change in plasma VE and oxalate concentrations. However, an increased tendency of oxalate concentration was found in the VC group, suggesting a possibly adverse side effect of long-term intravenous VC.
ERW decreased HD-enhanced ROS and PCOOH in the plasma and RBC membrane
In our previous studies, 3, 4 a single session of HD did not affect the levels of lipid profiles in the ESRD patients. The baseline level of pre-HD plasma phosphatidylcholine hydroperoxide (PCOOH) and erythrocyte membrane PCOOH was similar among the four groups of patients. However, in the XERW group, the post-HD plasma PCOOH (205724 pmol/ ml) and post-HD erythrocyte membrane PCOOH levels (310739 pmol/ml) were significantly (Po0.05) increased after HD (Figure 3 ). Intravenous VC significantly (Po0.05) prevented increases in post-HD plasma PCOOH (1107 15 pmol/ml) and in post-HD RBC membrane PCOOH levels (168725 pmol/ml). In the VE group, the VE-coated dialyzer also decreased the increase in post-HD plasma PCOOH level (145721 pmol/ml, Po0.05). On the other hand, the VEcoated dialyzer also prevented the increase in post-HD RBC membrane PCOOH levels (178729 pmol/ml, Po0.05). In the ERW group, ERW treatment significantly reduced post- HD plasma PCOOH (134718 pmol/ml, Po0.05) and post-HD RBC membrane PCOOH levels (163719 pmol/ml, Po0.05).
ERW reduced HD-triggered metHb formation
A single session of HD inhibited the activities of NADHmetHb reductase and NADH-ferricyanide reductase in erythrocytes, and it increased plasma metHb levels ( Figure 4 ). Intravenous VC, VE, or ERW treatment significantly preserved the activities of erythrocyte ferricyanide reductase and erythrocyte metHb reductase, and decreased the HDaugmented metHb level. These findings imply that ERW treatment was effective in preventing oxidative stress on erythrocytes.
Long-term effect of ERW on HD-induced oxidative stress and inflammatory markers
To determine the long-term effects of ERW in the ESRD patients undergoing chronic HD, we recorded the post-HD blood ROS, post-HD levels of activities of NADH-metHb reductase and NADH-ferricyanide reductase in erythrocyte membrane, and post-HD plasma metHb level in the ERWand XERW-treated patients for 6 months. As shown in Figure 5 , after 6 months of ERW treatment in the ESRD patients with chronic HD, the increased post-HD blood ROS was decreased (Po0.05) when compared to XERW group, whereas the post-HD levels of activities of NADH-metHb reductase and NADH-ferricyanide reductase were increased (Po0.05) when compared to the XERW group. The post-HD plasma metHb level was also significantly decreased (Po0.05) in the ERW group when compared to the XERW group. The long-term outcome showed that 6-month ERW treatment significantly increased hematocrit (from 28.970.7 to 31.570.6%) at a similar dose of erythropoietin administration in the 43 chronic HD patients ( Figure 6 ). However, the differences of hematocrit change were not statistically significant in the XERW group (from 31.071.0 to 30.77 0.4%) even at a similar dose of erythropoietin. Furthermore, after 6 months of ERW treatment, 26 plasma cytokines critical to the inflammatory response are also downregulated ( Figure 7 ). (3) inhibition of the activity of erythrocyte reductases, leading to hemolysis. The application of ERW can decrease HD-enhanced blood ROS production, RBC lipid peroxidation, and hemolysis via the preservation of NADH-ferricyanide reductase and -metHb reductase activity. This beneficial long-term outcome of 6-month ERW treatment can improve the hematocrit without the increment of erythropoietin dosage.
The oxidative stress associated with uremia is exacerbated by hemodialysis since neutrophils and monocytes, activated by contact with the dialysis membranes, release large amounts of ROS. [1] [2] [3] [4] The deleterious effects of ROS on carbohydrates, lipids, and proteins have a pathological role in many inflammatory diseases, most of which are frequent in HD patients. 5, 12 In particular, the oxidation of polyunsaturated fatty acids on the RBC membrane 3, 4, 12 increases RBC rigidity and reduces their deformability, 32, 33 leading to greater susceptibility to hemolysis, 4 and shorter survival. 15 ROS may cause subsequent oxidation and release of other oxidized metabolites and are increased after HD session. 3, 4 As a primary peroxidation product from membrane phospholipids, the level of PCOOH in the plasma and erythrocyte membrane was increased by HD. 3, 4 Further, the significant increases of metHb and the decreased activity of two RBC reductases (NADH-ferricyanide reductase and -metHb reductase) in post-HD plasma and RBC implicate potential RBC damage secondary to lipid peroxidation. Human oxyhemoglobin reacts with Fe(II)(CN) 5 H 2 O 3À to yield H 2 O 2 and metHb. 22 Further, metHb production can be accelerated by H 2 O 2 . 34 In our previous study, HD-triggered H 2 O 2 formation was positively correlated with the degree of hemolysis and with metHb levels. Based upon the interesting clinical improvement of a variety of diseases by intake of reduced water since 1985, Hayashi 35 proposed the hypothesis 'Water Regulating Theory' . The ideal scavenger for ROS should be active atomic hydrogen. Active atomic hydrogen can be produced in ERW near the cathode during electrolysis of water. ERW exhibits high pH, low dissolved oxygen, extremely high dissolved molecular hydrogen, and extremely negative redox potential values. 30 Shirahata et al. 30 suggest that the superoxide dismutase-and catalase-like activity of ERW is not owing to the dissolved molecular hydrogen but owing to the active atomic hydrogen with a higher reducing ability that may participate in ROS-scavenging activity. Happe et al. 36 indicate that hydrogenases, which are among in the oldest enzymes (3.8 billio years old), can reversibly split molecular hydrogen to produce active atomic hydrogen, which participates in the redox regulation of cellular function. The ROS-scavenging activity of ERW is stable at 41C for over a month and was not lost even after neutralization, repeated freezing and melting, deflation with sonication, vigorous mixing, boiling, repeated filtration, or closed autoclaving, but was lost by opened autoclaving or by closed autoclaving in the presence of tungsten trioxide which efficiently adsorbs active atomic hydrogen. 30 Active hydrogen in ERW may also be an ideal scavenger against ROS because it does not produce oxidized molecules after reduction like other organic antioxidants (VC, VE, and polyphenols).
3,31 ERW, VC and catechins completely scavenged O 2 ÀK produced by the hypoxanthine-xanthine oxidase system in sodium phosphate buffer. 30 Furthermore, ERW, catalase and VC could directly scavenge
3, 30 We found that ERW and epigallocatechin-3-gallate can scavenge both H 2 O 2 and HOCl, but VC only availably removes H 2 O 2 . The scavenging ROS mechanism by ERW may be due to the direct adsorption of ROS by active atomic hydrogen, because no antioxidant production by TAS assay was detected in our previous 3 and the present experiment. Furthermore, in spite of the presence of ERW, our previous report showed a significant increase in plasma PCOOH and a decrease in TAS from pre-to post-dialysis in the ESRD patients, whereas the present study showed no difference in PCOOH and TAS from pre-to post-dialysis in the ESRD patients. This discrepancy may be due to a diet control in the present study, because a dietary factor increased plasma triglyceride and very low-density lipoprotein levels, which could lead to an increase in PCOOH level and a reduction in TAS from pre-to post-dialysis even in the presence of ERW in our previous study. 3 This result indicates that ERW with a higher reducing ability and/or direct ROS-scavenging activity could be used in HD patients by its stable characteristics, cheaper expense, and strong antioxidant activity to relieve HD-evoked oxidative stress, preserve the activity of erythrocyte reductases and, and increase hematocrit during six months of treatment. Furthermore, it is well known that VC overdoses or long-term usage may cause secondary oxalosis via an increase in plasma oxalate levels and the deposition of calcium oxalate in various tissues. 4, 37 Therefore, the application of ERW treatment could prevent the increased plasma oxalate level during a single HD session or after six-month treatment.
ESRD patients on maintenance HD show systemic inflammation due to uremia and dialysis and suffer from cardiovascular events [7] [8] [9] [10] [11] and severe anemia. 38 HD-augmented hemolysis has been proposed as a significant factor in regard to HD-related shortened erythrocyte survival. 28 VE supplementation for HD patients resulted in reduced erythropoietin dosage requirements. 16 HD patients with stable hemoglobin levels and not receiving erythropoietin therapy exhibited a higher OH-scavenging activity when compared with those in need of erythropoietin: 39 it may be argued that erythropoietin or anemia-associated increments in the oxidant burden may be counterbalanced by a higher consumption of antioxidants like VC. Tarng et al. 40 reported that the dose of erythropoietin as well as the ratio of erythropoietin/hemoglobin was found to correlate positively with serum concentrations of 8-hydroxy-2 0 -deoxyguanosine, an oxidation product of DNA. VC influenced renal synthesis of erythropoietin in the kidneys, and production of erythropoietin was enhanced in the presence of antioxidative cocktail comprising vitamins A, E, and C. Also, pro-oxidants reduced erythropoietin synthesis in human hepatoma cells. 41 Our data showed that 6 months of antioxidant ERW treatment significantly increased hematocrit but did not increase erythropoietin dose in the 43 ESRD patients. Antioxidants like VE and anti-inflammatory drugs can attenuate chronic HD-evoked cardiovascular events and neutrophil and endothelial cell apoptosis. [41] [42] [43] [44] The present results showed that 26 proinflammatory cytokines are downregulated after 6 months of ERW treatment. These findings provide new insight into the molecular events that resolve anemia and inflammation in chronic HD patients by the ERW treatment. A further study for clarification of ERW on immunity needs to be determined.
In conclusion, our findings demonstrate that ERW treatment is effective in palliating HD-evoked oxidative stress, as indicated by hemolysis and lipid peroxidation, in HD patients. Long-term benefits of this novel therapy are associated with an increase of hematocrit level, improvement of erythropoietin responsiveness, and downregulation of proinflammatory cytokines in chronic HD patients.
MATERIALS AND METHODS Patients
To assess the extent of oxidative stress in blood of ESRD patients, 25 patients (14 men and 11 women) without any treatment (XERW group), 15 patients (seven men and eight women) with intravenous VC group (1 g in 250 ml of saline infused over 4 h of HD), 15 patients (eight men and seven women) with VE-coated dialyzer (VE group), 43 patients (28 men and 15 women) subjected to ERW treatment (ERW group) with 10.870.5 mg/dl of creatinine, subjected to maintenance HD at Wan-Hwa Hospital for a period of 1272 months after informed consent obtained were enrolled in the ERW study. The criteria for patient selection included the absence of habit of smoking, malignancy, inflammatory disorders, chronic or acute infections, supplementation of VC or VE, and treatment either oral or intravenous iron, or anti-inflammatory drugs 3 months before enrollment. The mean age was 5873 years old (mean7s.e.m., range 42-82 years). As the subjects for 6-month study were recruited into the ERW and XERW groups, we found that at entry the study the XERW group had a high, but not significant, baseline hematocrit level than the ERW group (31.071.0 vs 28.970.7%, P ¼ 0.097). A similar level in blood urea nitrogen (63.572.7 vs 71.473.3 mg/dl, P ¼ 0.07), creatinine (10.070.35 vs 11.070.51 mg/dl, P ¼ 0.10), albumin (3.8270.05 vs 3.7870.07 g/dl, P ¼ 0.57), and ferritin (395720 vs 373738 ng/ml, P ¼ 0.596) was noted in the ERW and XERW groups. All HD patients except VE group used hemodialyzer (AM-Bio-HX-90 and AM-Bio-HX-100 biomembrane: Asahi Kasei Med Co., Tokyo, Japan). A VE-coated EE18 Excerbrane s membrane (Terumoc Co., Japan) was used in the VE group. The VC solution (Tai-Yu Pharmaceutical, Taipei, Taiwan) was prepared in 1 g/250 ml of saline before use. The blood flow rate during the dialysis sessions was 250-300 ml/min and dialysate flow 500 ml/min. The surface area of these two dialyzers was 1.5 and 1.8 m 2 , respectively, and patient treatment with either membrane lasted for 6 montha. The kt/v of all these patients is maintained between 1.3 and 1.6. The cause of ESRD was diabetes in 55 patients and chronic glomerulonephritis in 43 patients. HD patients were on a free diet with a normal and constant intake of essential fatty acids, and none of them took any drug with established or potential oxidizing effect and any antioxidants such as VC or VE during 6 months of tested period. The permission of clinical trial was approved by the meeting of Human Research Committee of the Wan-Hwa Regional Hospital.
ERW system HD-24K (Nihom Trim Co., Osaka, Japan) was structured as described in detail previously. 3 In brief, raw water was supplied after compressed by the compression pump and supplied into a compartment for electrolysis through a solanoid valve, which opens and closes synchronizing with the signal of water level sensor in electrolyzed water storage tank and flow sensor. At the electric compartment, the supplied raw water was electrolyzed by direct current supplied to þ and À electrode plate across diaphragm and at the side of À electrode plate reduced water containing active hydrogen and lower redox potential value. The series of operation are automatically carried out according to the level of reduced water tank. HD-24K, compression pump, reduced water tank, acidic water tank, and personal computer for control are placed in front of usual raw water processing device. The reduced water produced by HD-24K was collected in reduced water tank, and then was supplied to usual raw water processing system for HD by compress with compressing pump. The intensity of electrolysis of HD-24K is adjusted to 'level 2' and the ERW that indicates pH 9.8 right after taking from 'out' of HD-24K is used in this study. The quality of ERW for HD was approved by Yen Tjing Ling Industrial Research Institute National Taiwan University with the No. E89A299D277, which is required by the American Association of Medical Instruments (AAMI). The ERW dialysates maintain the properties of lower redox potential value when compared to that of the non-ERW dialysate (15075 29675 mV). The microbiological quality of the final dialysates meets the AAMI standard (obacteria of 200 colony-forming units/ml and oendotoxin concentration of 2 EU/ml). Because culture results do not become available for at least 48 h, during which time bacteria continue to proliferate, the final dialysate action level also meet AAMI standard (obacteria and endotoxin of 50 colony-forming units//ml and 1 EU/ml, respectively). The endotoxin level in the water used for HD is 0.06170.003 EU/ml measured by an endotoxin ELISA kit (HBT-HIT301, Biocompare Inc., South San Francisco, CA, USA) and an automated ELISA analyzer (CODA, SN10373, Hercules, CA, USA).
Blood samples and biochemical analysis Blood (10 ml) was collected via the arterial line of the HD circuit, before the start and the end of an HD session, into a heparinized sterile test tube and was processed within 2 h. Concerning the effects of hemoconcentration during HD, the post-HD levels of various plasma biochemicals were corrected with the following equation:
Corrected post À HD value ¼measured post À HD value ÂðC preÀHD =C postÀHD Þ
The whole-blood cell count, including the hemoglobin level and hematocrit, were determined with an autoanalyzer (Coulter STKS, Hialeah, Finland). Plasma levels of urea nitrogen and creatinine were determined with an autoanalyzer (Hitachi 736-15, Ibaraki, Japan). The plasma oxalate concentration was determined by an enzymatic method.
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Measurement of ROS activity in whole blood and plasma To determine the ROS activity in whole blood and plasma, we sampled and isolated plasma from the four groups of patients at various time points through the first HD session of the study. After sampling, 0.2 ml of whole blood or plasma was immediately added to the luminol solution, and ROS signals were measured as described previously. 4 To identify the types of ROS in the HD-activated blood, we studied the effects of various ROS inhibitors, including superoxide dismutase (an O 2 ÀK scavenger, 30 U), catalase (an H 2 O 2 scavenger, 30 U), and epigallocatechin-3-gallate (an HOCl and H 2 O 2 scavenger, 10 mg). 4 To test the in vitro effects of ERW, we also compared the ROS signals in blood samples obtained from the N group before and after treatment with ERW.
Plasma VC and VE assay
To preserve VC, an aliquot of plasma was deproteinized with 10% metaphosphoric acid (1:1, vol/vol), and the supernatant was kept at À801C. Plasma VC was measured by high-performance liquid chromatography (Hitachi D-7000 HPLC system) with ultraviolet detector at 254 nm with a Cosmosil 5 C 18 -MS column (250 Â 4.6 mm ID) with a 5-mm particle size. 45 VE was measured, after extraction with ethanol and hexane, by high-performance liquid chromatography with UV detection at 292 nm 46 with a Cosmosil 5C 18 -MS column (150 Â 4.6 mm ID) with a 5-mm particle size. The system manager software (D-7000, version 3.0; Hitachi) was used for VC and VE peak integration and data acquisition.
The extraction recoveries of standards recoveries of VC and VE within the concentration range of the assay were 85 and 96%. For VC and VE, within-day variability was lower than 13.5%, whereas between-day variability did not exceed 14.8%. Within-day variability averaged 11.472.5% for VC and 6.171.6% for VE. Mean betweenday variability was 11.972.7% for VC and 6.371.5% for VE.
Measurements of plasma TAS
We measured the TAS of plasma (20 ml) by a commercial kit (TAS kit, Randox, San Franciso, CA, USA) according to the manufacturer's instructions. 3, 4 Measurement of lipid peroxidation products A lipid peroxidation product, PCOOH, originating from oxidized phosphatidylcholine is a primary lipid peroxidation product, 47 which was measured to serve as an indication of oxidative stress. 3, 4 The amounts of PCOOH in plasma and erythrocytes were determined in duplicate by chemiluminescence high-performance liquid chromatography (CL-HPLC, Tohoku Electronic Ind. Co., Sendai, Japan).
Spectrophotometric assessment of oxidized hemoglobin and RBC reductase activities HD-induced oxidative stress, via erythrocyte membrane lipid peroxidation, would lead to erythrocyte destruction and hemoglobin release. We determined the plasma concentration of metHb spectrophotometrically, as described previously. 34 The hemolysis score was determined by spectrophotometric measurement at 540 nm, and with a Coulter counter (Coulter Onix, Miami, FL, USA). A reduced activity of RBC trans-plasma membrane electron transport system, including ferricyanide reductase and metHb reductase, could lead to cell damage and increase plasma metHb and H 2 O 2 concentration.
28,29 RBC ferricyanide reductase activity was measured as described previously. 48 metHb reductase activity was assayed by use of 2,6-dichlorophenol indophenol as an electron acceptor. 49 
Statistical analysis
All values are expressed as mean7s.e.m. Within-group comparisons between pre-and post-HD values were performed by paired t-test. For longitudinal data, repeated measures analysis of variance with post hoc analysis with the Bonferroni procedure were used to analyze the between-and within-group differences. Po0.05 was adopted as indicating statistical significance.
